Schrodinger posts corporate presentation on computational platform for drug and materials discovery

Schrodinger

Schrodinger

SDGR

0.00
  • Schrodinger outlined strategy to scale its physics-based simulation and AI platform across life sciences and materials, including planned early-access release of Bunsen, an agentic AI system designed to automate molecular discovery workflows.
  • Software business tracked $201 million trailing four-quarter annual contract value; 2026 outlook called for ACV of $218 million-$228 million, implying 10%-15% growth over 2025.
  • Management highlighted shift toward hosted software to smooth revenue recognition, noting hosted revenue already represented 23% of software revenue.
  • 1Q 2026 revenue totaled USD 58.6 million; software revenue fell 21% to USD 35.6 million while drug discovery revenue rose 124% to USD 22.9 million.
  • Cash and marketable securities were USD 406.4 million as of March 31, 2026; 2028 objectives included positive adjusted EBITDA by end-2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Schrodinger Inc. published the original content used to generate this news brief on May 06, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.